title: B-ALL minimal residual disease flow cytometry: an application of a novel method for optimization of a single-tube model.
abstract: OBJECTIVE
  Optimizing a clinical flow cytometry panel can be a subjective process dependent on experience. We develop a quantitative method to make this process more rigorous and apply it to B lymphoblastic leukemia/lymphoma (B-ALL) minimal residual disease (MRD) testing.
  
  
  METHODS
  We retrospectively analyzed our existing three-tube, seven-color B-ALL MRD panel and used our novel method to develop an optimized one-tube, eight-color panel, which was tested prospectively.
  
  
  RESULTS
  The optimized one-tube, eight-color panel resulted in greater efficiency of time and resources with no loss in diagnostic power.
  
  
  CONCLUSIONS
  Constructing a flow cytometry panel using a rigorous, objective, quantitative method permits optimization and avoids problems of interdependence and redundancy in a large, multiantigen panel.
authors: From the Vanderbilt University Medical Center, Nashville, TN, and aaron.shaver@vanderbilt.edu.
authors: Aaron C
authors: AC
authors: Shaver
authors: From the Vanderbilt University Medical Center, Nashville, TN, and.
authors: Bruce W
authors: BW
authors: Greig
authors: From the Vanderbilt University Medical Center, Nashville, TN, and VA Tennessee Valley Healthcare System, Nashville.
authors: Claudio A
authors: CA
authors: Mosse
authors: From the Vanderbilt University Medical Center, Nashville, TN, and.
authors: Adam C
authors: AC
authors: Seegmiller
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002648:Child; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D016130:Immunophenotyping; D008297:Male; D018365:Neoplasm, Residual; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis*; D011379:Prognosis; D011446:Prospective Studies; D015203:Reproducibility of Results; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor
keywords: Acute lymphoblastic leukemia; Flow cytometry; Minimal residual disease; Optimization; Statistical analysis